Preview

Кардиология

Расширенный поиск

Ключевые моменты рекомендаций ACC/AHA/HRS 2017 по диагностике и лечению обмороков

https://doi.org/10.18087/cardio.2018.8.10151

Полный текст:

Об авторах

Г. А. Головина
ГБУЗ «НИИ - Краевая клиническая больница № 1 им. проф. С. В. Очаповского» Минздрава Краснодарского края
Россия


Д. В. Дупляков
ГБУЗ «Самарский областной клинический кардиологический диспансер» Минздрава России; ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России
Россия


Список литературы

1. Shen W. K., Sheldon R. S., Benditt D. G. et al. 2017 ACC/AHA/ HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J. Am Coll Cardiol 2017pii: S0735-1097 (17) 30793-3. DOI: 10.1016/j.jacc. 2017.03.003. [Epub ahead of print]

2. Brignole M., Alboni P., Benditt D. G. et al. Guidelines on management (diagnosis and treatment) of syncope-Update 2004. Europace 2004;6:467-537.

3. Moya A., Sutton R., Ammirati F. et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30:2631-2671.

4. Martin T. P., Hanusa B. H., Kapoor W. N. Risk stratification of patients with syncope. Ann Emerg Med 1997;29:459-466.

5. Sarasin F. P., Hanusa B. H., Perneger T. et al. A risk score to predict arrhythmias in patients with unexplained syncope. Acad Emerg Med 2003;10:1312-1317.

6. Colivicchi F., Ammirati F., Melina D. et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score. Eur Heart J. 2003;24:811-819.

7. Quinn J. V., Stiell I. G., McDermott D. A. et al. Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med 2004;43:224-232.

8. Costantino G., Perego F., Dipaola F. et al. Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the STePS (Short-Term Prognosis of Syncope) study. J. Am Coll Cardiol 2008;51:276-283.

9. Del Rosso A., Ungar A., Maggi R. et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart 2008;94:1620-1626.

10. Grossman S. A., Fischer C., Lipsitz L. A. et al. Predicting adverse outcomes in syncope. J. Emerg Med 2007;33:233-239.

11. Reed M.J., Newby D. E., Coull A.J. et al. The ROSE (Risk Stratification of Syncope in the Emergency Department) study. J. Am Coll Cardiol 2010;55:713-721.

12. Sun B. C., Derose S. F., Liang L.J. et al. Predictors of 30-day serious events in older patients with syncope. Ann Emerg Med 2009;54:769-778.

13. Shin T. G., Kim J. S., Song H. G. et al. Standardized approaches to syncope evaluation for reducing hospital admissions and costs in overcrowded emergency departments. Yonsei Med J. 2013;54:1110-1118.

14. Page R. L., Joglar J. A., Caldwell M. A. et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2014;129:2440-2492.

15. Nishimura R. A., Otto C. M., Bonow R. O. et al. 2014AHA/ACC guideline for the management ofpatients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:2440-2492.

16. Epstein A. E., DiMarco J. P., Ellenbogen K. A. et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF / AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013;127: e283-352.

17. Zipes D. P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report ofthe American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Circulation 2006;114:1088-1132.

18. January C. T., Wann L. S., Alpert J. S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130: e199-267.

19. Gersh B.J., Maron B.J., Bonow R. O. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of 'Horacic Surgeons. Circulation 2011;124: e783-831.

20. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management ofpatients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. G Ital Cardiol (Rome). 2016; 17:108-70.

21. Tracy C. M., Epstein A. E., Darbar D. et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation 2012;126:1784-800.

22. Russo A.M., Stainback R.F., Bailey S.R. et al. ACCF/HRS/AHA/ ASE/HFSA/SCAI/SCCT/SCMR2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013;61:1318-1368.

23. Antzelevitch C., Brugada P., Borggrefe M. et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005;2:429-440.

24. Priori S. G., Gasparini M., Napolitano C. et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012;59:37-45.

25. Morita H., Kusano K. F., Miura D. et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008;118:1697-1704.

26. Gaita F., Giustetto C., Bianchi F. et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003;108:965-970.

27. Giustetto C., Schimpf R., Mazzanti A. et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011;58:587-595.

28. Priori S. G., Wilde A. A., Horie M. et al. HRS /EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EH^A, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013; 10:1932-63.

29. Priori S. G., Napolitano C., Schwartz P.J. et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341-1344.

30. Abu-Zeitone A., Peterson D. R., Polonsky B. et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 2014;64:1352-1358.

31. Ouriel K., Moss A.J. Long QT syndrome: an indication for cervico-thoracic sympathectomy. Cardiovasc Surg 1995;3:475-478.

32. Collura C. A., Johnson J. N., Moir C. et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catechol-aminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009;6:752-759.

33. Haïssaguerre M., Derval N., Sacher F. et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008;358:2016-2023.

34. Rosso R., Kogan E., Belhassen B. et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol 2008;52:1231-1238.

35. Derval N., Simpson C. S., Birnie D. H. et al. Prevalence and characteristics of early repolarization in the CASPER registry: cardiac arrest survivors with preserved ejection fraction registry. J Am Coll Cardiol 2011;58:722-728.

36. Mahida S, Derval N, Sacher F et al. Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015; 65:151-9.

37. Van Dijk N., Boer K. R., Colman N. et al. High diagnostic yield and accuracy of history, physical examination, and ECG in patients with transient loss of consciousness in FAST: the Fainting Assessment study. J Cardiovasc Electrophysiol 2008;19:48-55.

38. Perez-Lugones A., Schweikert R., Pavia S. et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol 2001;12:935-938.

39. Ward C. R., GrayJ. C., GilroyJ.J. et al. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998;79:45-49.

40. Romme J. C. M., van Dijk N., Go-Schön I. K. et al. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STANDtrial). Europace 2011;13:1639-1647.

41. Liu J. F., Jons C., Moss A.J. et al. Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011;57:941-950.

42. Sheldon R., Raj S. R., Rose M. S. et al. Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-Controlled trial. J Am Coll Cardiol 2016;68:1-9.

43. Salim M. A., Di Sessa T. G. Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: a double-blind, placebocontrolled, randomized trial. J Am Coll Cardiol 2005;45:484-488.

44. Sheldon R. S., Morillo C. A., Klingenheben T. et al. Age-dependent effect of beta-blockers in preventing vasovagal syncope. Circ Arrhythm Electrophysiol 2012;5:920-926.

45. Sheldon R., Rose S., Flanagan P. et al. Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am J Cardiol 1996;78:536-539.

46. Sutton R. Pacing in patients with carotid sinus and vasovagal syndromes. PACE 1989;12: 1260-1263.

47. Brignole M., Sartore B., Barra M. et al. Is DDD superior to VVI pacing in mixed carotid sinus syndrome? An acute and medium-term study. Pacing Clin Electrophysiol 1988;11:1902-1910.

48. Madigan N. P., Flaker G. C., Curtis J.J. et al. Carotid sinus hypersensitivity: beneficial effects of dual-chamber pacing. Am J Cardiol 1984;53:1034-1040.


Рецензия

Для цитирования:


Головина Г.А., Дупляков Д.В. Ключевые моменты рекомендаций ACC/AHA/HRS 2017 по диагностике и лечению обмороков. Кардиология. 2018;58(8):89-100. https://doi.org/10.18087/cardio.2018.8.10151

For citation:


Golovina G.A., Duplyakov D.V. Key Points of the 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Kardiologiia. 2018;58(8):89-100. (In Russ.) https://doi.org/10.18087/cardio.2018.8.10151

Просмотров: 893


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)